• USA Home
  • 217691 - CDC25 Phosphatase Inhibitor I, BN82002 - CAS 396073-89-5 - Calbiochem

EMAIL THIS PAGE TO A FRIEND
217691 Millipore

CDC25 Phosphatase Inhibitor I, BN82002 - CAS 396073-89-5 - Calbiochem

The CDC25 Phosphatase Inhibitor I, BN82002, also referenced under CAS 396073-89-5, controls the biological activity of CDC25 Phosphatase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Synonym: CDC25 Phosphatase Inhibitor I, BN82002 - CAS 396073-89-5 - Calbiochem, N-(2-Hydroxy-3-methoxy-5-dimethylamino)benzyl, Nʹ-(2-(4-nitrophenethyl)), Nʹʹ-methylamine, PTP Inhibitor XX

  • CAS Number 396073-89-5

  • Empirical Formula (Hill Notation) C19H25N3O4

  • Molecular Weight 359.42

Purchase

Properties

Quality Level   100
assay   ≥95% (HPLC)
form   solid
mfr. no.   Calbiochem®
storage condition   OK to freeze
  protect from light
storage conditions   -20C
color   red to dark red
solubility   DMSO: 10 mg/mL
  ethanol: 10 mg/mL
shipped in   ambient

Description

General description

A cell-permeable ortho-hydroxybenzylamino compound that displays anti-tumor properties. Acts as a potent, selective, and irreversible inhibitor of CDC25 phosphatase family (IC50 = 2.4, 3.9, 6.3, 5.4, and 4.6 µM for 25A, 25B2, 25B3, 25C, and 25C-cat, respectively). Displays ~20-fold greater selectivity for CDC25 phosphatases compared to CD45 tyrosine phosphatase. Shown to delay cell cycle progression in vitro (IC50 in the range of 7.2-32.6 µM), and reduces tumor growth in athymic mice xenografted with the human pancreatic cell MIA PaCa-2 (15 mg/kg, i.p. route).

A cell-permeable ortho-hydroxybenzylamino compound that displays antitumor properties. Acts as a potent, selective and irreversible inhibitor of CDC25 phosphatase family (IC50 = 2.4, 3.9, 6.3, 5.4, and 4.6 µM for 25A, 25B2, 25B3, 25C, and 25C-cat, respectively). Displays ~20-fold greater selectivity for CDC25 phosphatases over CD45 tyrosine phosphatase. Shown to delay cell cycle progression in vitro (IC50 = ~7.2-32.6 µM), and reduces tumor growth in athymic mice xenografted with the human pancreatic cells MIA PaCa-2 (15 mg/kg, i.p. route).

Packaging

5 mg in Plastic ampoule

Biochem/physiol Actions

Cell permeable: yes

Primary Target
CDC25A

Product does not compete with ATP.

Reversible: no

Target IC50: 2.4, 3.9, 6.3, 5.4, and 4.6 µM for CDC25 phosphatase family 25A, 25B2, 25B3, 25C, and 25C-cat, respectively

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Unstable in aqueous solution.

Other Notes

Brezak, M.C., et al. 2004. Cancer Res.64, 3320.

Safety & Documentation

Safety Information

Safety Information for this product is unavailable at this time.
Protocols & Articles
Related Products

Technical Service:

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Bulk Ordering & Pricing:

Need larger quantities for your development, manufacturing or research applications?